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The choice of a primary endpoint is an important issue when designing a clinical trial. It is common the use
of a composite endpoints as primary endpoint because it increases the number of observed events, captures
more information and is expected to increase the power. However, combining events which have not similar
clinical importance and have different treatment effects makes the interpretation of the results cumbersome
and might reduce the power of the corresponding tests. Go´mez and Lagakos proposed the ARE (Asymptotic
Relative Efficiency) method to choose between a composite or one of its components as primary endpoint
comparing the efficacy of a treatment based on the times to each of these endpoints. The aim of this paper is
to expand the ARE method to binary endpoints. We show that the ARE method depends on six parameters
including the degree of association between components, the event proportion and the effect of therapy
given by the corresponding odds ratio of the single endpoints. A case study is presented to illustrate the
methodology. We conclude with efficient guidelines for discerning which could be the best suited primary
endpoint given anticipated parameters.
Key words: Asymptotic Relative Efficiency; Binary Endpoint; Clinical Trial; Composite End-
point; Treatment Effects.
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1 Introduction
Nowadays, randomized clinical trials guide the advance of medical knowledge. They are the most well-
grounded procedure for evaluating the applicability of clinical research and also comparing the safety
and effectiveness of a new intervention against the standard of care. The protocol formalizes the medical
question and specifies the design of the trial. One key decision that has to be defined is the choice of the
primary endpoint which measures the clinical evidence by quantifying the treatment effect. Sample size
requirement, analysis and conclusions on efficacy are based on the primary endpoint.
Clinical trials often take into account two or more efficacy endpoints. If we use multiple co-primary
endpoints, we could capture different attributes. Moreover, multiple co-primary endpoint might provide a
better explanation about how the disease behaves under treatment and an improvement of the evaluation
of whether there are the differences in the efficacy between different interventions. However, the use of
multiple endpoints entails challenges in analyses and planning. On the one hand, we need a multiplicity
adjustment for avoiding an inflation of the overall type I error (Pocock, et al. (1987)). On the other
hand, multiple co-primary endpoints are usually correlated between them. Since the correlation affects
parameters estimation and sample size calculation, we should correctly specify them, because if we define
the endpoints as if they were not correlated, we will not achieve the desired power (Sozu, et al. (2010)).
One possible approach to deal with these challenges is to transform the multivariate problem into a
univariate one combining several outcomes in a single summary indicator (Rauch, et al. (2014)). In this
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regard, it is common to use the combination of several responses into a unique variable, specially in the
settings of time-to-event and binary outcomes. Then, the focus is on the time of first event between a set of
possible adverse events which are assumed to be relevant to the disease progress, or, in the binary context,
the composite collapses the information into a binary endpoint which takes value 1 if whenever one of the
outcomes has occurred.
Composite endpoints are frequently chosen as primary endpoint in many health areas and specially in
cardiovascular and oncology trials. There are three key advantages for using a composite. First, they
avoid the need of multiplicity adjustment. Second, a composite endpoint contains more information on the
course of the disease than a single endpoint providing a better explanation about the differences between
treatment groups. Third, the increment of the number of observed events is expected to increase the power
(Rauch, et al. (2014)).
The main drawback of using a composite endpoint is its interpretation since its components rarely
have comparable clinical importance and similar treatment effects (Ferreira-Gonza´lez, et al. (2007)).
Besides, a combination of different events changes the mean and also the variance of the response upon
which the analysis is based (Lefkopoulou and Ryan (1993)). The addition of components which are not
relevant enough could compromise the interpretation of results and reduce power. Hence, the choice of the
particular components for the composite has a great importance in the design phase (Mascha and Sessler
(2011)) and a deeper study about the meaning of the composite response is needed (Rauch and Kieser
(2013)).
Legler, et al. (1995) and Lefkopoulou and Ryan (1993) presented a framework for comparing the
performance of several tests based on multiple binary endpoints. They compare as well those tests to the
test that results of collapsing the data into a composite. In the framework of survival analysis, Go´mez and
Lagakos (2013) proposed the Asymptotic Relative Efficiency (ARE) method to compare the efficiencies
of two trial designs according to the chosen primary endpoint. The motivation lied in deciding between
one relevant primary endpoint or the compound of this relevant and one additional endpoint as primary
endpoint of the trial. Their methodology, referred to as the ARE method, provides a tool to quantify the
improvement in efficiency of adding a secondary endpoint to the primary endpoint. However, the ARE
method has not been studied for binary outcomes.
Assume a binary composite endpoint and also the most severe and relevant of its components. Aiming
to provide statistical guidelines that would indicate when it is more efficient to use the composite endpoint
over one of its components as the primary endpoint of the trial, we expand the ARE method proposed by
Go´mez and Lagakos to binary endpoints. We show that the ARE method for binary composite endpoint
depends on six parameters including the degree of association between the components of the composite
endpoint on each group, the event proportion, and the effect of therapy on each component.
The paper is structured as follows, first, we relate the parameters of the composite to the parameters
of the components and the correlation between them. Then, we find a relationship between the odds ratio
of the composite and the odds ratios of its components. After that, we define the extension of the ARE
method for binary endpoints and we explain the applicability of the method. Next, a clinical trial is used
to illustrate the use of the methodology. Finally, we present recommendation guidelines in order to assess
in which cases a composite endpoint should be preferred because is more efficient than the most relevant
of its components. A short discussion concludes the paper.
2 Notation and main assumptions
2.1 Binary endpoints
Consider a randomized clinical trial comparing two treatment groups, control group (i = 0) and treatment
group (i = 1), each group composed of ni patients and denoting by n = n0 + n1 the total number of
patients. We assume two different binary endpoints of potential interest, ε1 and ε2. Let Xijk denote
the response of the k-th binary endpoint for the j-th patient in the i-th group of treatment (i = 0, 1,
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j = 1, ..., ni, k = 1, 2). The response Xijk is defined by 1 if the event, εk, has occurred and 0 otherwise.
Then, for all j ∈ {1, ..., ni}, i ∈ {0, 1}, k ∈ {1, 2}, the event rates are defined as:
p
(i)
k = P(Xijk = 1) = 1− q(i)k
where p(i)k and q
(i)
k are the probabilities that εk occurs or not, respectively, for a patient belonging to the
i-th group of treatment.
We consider a binary composite endpoint of two components, ε∗ = ε1 ∪ ε2, defined as the event that
occurs whenever one of the endpoints is observed. Moreover, we assume that there exists one endpoint
which is more relevant for the scientific question than the other, with no loss of generality, consider ε1 the
relevant endpoint and ε2 the additional one. Denote by Xij∗ the composite response defined as a Bernoulli
random variable of parameter p(i)∗ = P(Xij∗ = 1) = 1− q(i)∗ , where
Xij∗ =
{
1, if Xij1 +Xij2 ≥ 1
0, if else Xij1 +Xij2 = 0
In order to quantify the differences in efficacy between the two treatments, we might use the odds ratio for
each k-th endpoint defined as:
ORk =
p
(1)
k /q
(1)
k
p
(0)
k /q
(0)
k
Hereafter, we assume that both the composite endpoint and the relevant endpoint could lead to answer the
clinical question, that is, both might be used as the primary endpoint of the trial.
2.2 The relevant endpoint as primary endpoint
If we test the treatment effect on the relevant endpoint, we establish the following hypothesis test:
H1 :
{
H0 : log(OR1) = 0
H1 : log(OR1) < 0
(1)
where the null hypothesis of no-treatment effect is stated as OR1 = 1 or equivalently log(OR1) = 0 and
the alternative hypothesis assumes a risk reduction of the relevant endpoint, then, a negative log(OR1).
For addressing the problem, we consider the score test defined as:
T1,n =
pˆ
(0)
1 − pˆ(1)1√
1
n0
pˆ
(0)
1 qˆ
(0)
1 +
1
n1
pˆ
(1)
1 qˆ
(1)
1
(2)
where pˆ(i)1 =
1
ni
∑ni
j=1Xij1 = 1 − qˆ(i)1 , that is, the proportion of relevant events in the i-th group of
treatment.
Under the null hypothesis, the score test asymptotically follows the standard normal distribution. Under
contiguous alternatives of the form H1,n : log(OR1)n = v1√n , where v1 < 0, the score test is asymptoti-
cally normal with unit variance and mean δ1, called non-centrality parameter of the test, given by:
δ1 = v1
√
p
(0)
1 q
(0)
1 pi(1− pi) (3)
where pi denotes the proportion of patients allocated to control group, that is, pi = limn→+∞ n0/n.
For any finite sample size, log(OR1)n = v1√n is the treatment effect assumed as alternative. The effects
are determined by the sample size and the constant v1 which is interpreted as the limiting treatment effect
as sample size increases, i.e.:
lim
n→+∞
√
n log(OR1)n = v1
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Since the contiguous alternative changes with n, it forms a sequence that converge to 0, that is, to the null
hypothesis as n → +∞. Whereas the power of the score test under any fixed alternative goes to 1 as
sample size goes to infinity, under contiguous alternatives the limiting power is strictly less than 1.
2.3 The composite endpoint as primary endpoint
If the treatment effect is evaluated at the composite endpoint, the hypotheses are defined by:
H∗ :
{
H0 : log(OR∗) = 0
H1 : log(OR∗) < 0
(4)
where under the null hypothesis, we assume that there is not treatment effect on the composite endpoint
and, under the alternative hypothesis, we state a reduction of the risk evaluated on the composite event.
Following the same procedure as above, the difference between treatment groups is tested by means of
the score test, T∗,n, namely:
T∗,n =
pˆ
(0)
∗ − pˆ(1)∗√
1
n0
pˆ
(0)
∗ qˆ
(0)
∗ + 1n1 pˆ
(1)
∗ qˆ
(1)
∗
(5)
The score test T∗,n under the null hypothesis is asymptoticallyN(0, 1), and under a sequence of contiguous
alternatives, H∗,n : log(OR∗)n = v∗√n , is asymptotically normal with unit variance and mean δ∗ (non-
centrality parameter) given by:
δ∗ = v∗
√
p
(0)
∗ q
(0)
∗ pi(1− pi) (6)
3 Binary Composite Endpoint defined from the margins
3.1 Parameters
Bahadur’s theorem (Bahadur (1961)) allows to determine the joint distribution of multiple correlated bi-
nary endpoints and shows that the joint distribution is uniquely determined by the marginal probabilities
and the degree of association between the endpoints. As noted by Sozu, et al. (2010), the association de-
gree among the correlated binary endpoints might be defined by different measures. We consider Pearson’s
correlation coefficient as the association measure between endpoints. Let ρ(i) be the correlation coefficient,
also referred as phi coefficient, in the i-th group defined as:
ρ(i) =
p
(i)
∩ − p(i)1 p(i)2√
p
(i)
1 q
(i)
1 p
(i)
2 q
(i)
2
Note that the correlation coefficient is represented by the underlying probabilities and the overlap between
these marginal events, expressed by p(i)∩ = P(Xij1 = 1, Xij2 = 1). Applying results from Bahadur
(1961), the probability of the composite endpoint in the i-th group of treatment, p(i)∗ , is uniquely determined
by the probabilities of the single endpoints, p(i)1 , p
(i)
2 , and the correlation between them, as follows:
p
(i)
∗ = 1− q(i)1 q(i)2 − ρ(i)
√
p
(i)
1 p
(i)
2 q
(i)
1 q
(i)
2 , i = 0, 1
The odds ratio of the composite endpoint, OR∗, is given in terms of the correlation between endpoints for
each group, the event proportions in the control group given by the respective odds and the therapy effect
given by the corresponding odds ratio, as follows:
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OR∗ =
(
1+
OR1p
(0)
1
1−p(0)1
)(
1+
OR2p
(0)
2
1−p(0)2
)
−1−ρ(1)
√
OR1OR2p
(0)
1 p
(0)
2
(1−p(0)1 )(1−p
(0)
2 )
1+ρ(1)
√
OR1OR2p
(0)
1 p
(0)
2
(1−p(0)1 )(1−p
(0)
2 )(
1+
p
(0)
1
(1−p(0)1 )
)(
1+
p
(0)
2
(1−p(0)2 )
)
−1−ρ(0)
√
p
(0)
1 p
(0)
2
(1−p(0)1 )(1−p
(0)
2 )
1+ρ(0)
√
p
(0)
1 p
(0)
2
(1−p(0)1 )(1−p
(0)
2 )
(7)
The full derivation is to be found in Appendix A. Observe that OR∗ depends on the following six parame-
ters (p(0)1 , p
(0)
2 ,OR1,OR2, ρ
(0), ρ(1)) and that the parameters associated to each component together with
the correlation between them is what we only need to assess the effect on the composite endpoint.
A special property of binary endpoints is that the correlation takes values between two bounds which
are defined according to the marginal probabilities (Prentice (1988)) –the parametric space of ρ(i) is more
confined than (−1, 1)–, that is:
ρ(i) ∈ [m(p(i)1 , p(i)2 ), M(p(i)1 , p(i)2 ) ] ⊆ [−1, 1]
where:
m(p
(i)
1 , p
(i)
2 ) = max
−
√√√√p(i)1 · p(i)2
q
(i)
1 · q(i)2
,−
√√√√ q(i)1 · q(i)2
p
(i)
1 · p(i)2

M(p
(i)
1 , p
(i)
2 ) = min
+
√√√√p(i)1 · q(i)2
p
(i)
2 · q(i)1
,+
√√√√p(i)2 · q(i)1
p
(i)
1 · q(i)2

3.2 Treatment effects and non-equivalence between hypotheses
It can be easily proved by inspection of (7) that if the treatment has no effect on any of the marginal
components and the correlation between them is the same in the two groups, then, the treatment has no
effect on the composite endpoint, that is:
OR1 = 1, OR2 = 1, ρ
(0) = ρ(1) =⇒ OR∗ = 1
Note that this result could be restated in terms of the event proportions:
p
(0)
1 = p
(1)
1 , p
(0)
2 = p
(1)
2 , ρ
(0) = ρ(1) =⇒ p(0)∗ = p(1)∗
However, the reciprocal is not necessarily true, that is to say, the effect of treatment on any endpoint
(OR1 < 1 or OR2 < 1) could be diluted on the composite (OR∗ = 1). This complex relationship between
the odds ratios of each component and the composite shows how the treatment effects are differently
measured on each endpoint, and cannot be taken as equivalent. Thus, the two hypothesis tests being
considered to test the treatment effect on either endpoint, H1 (stated in (1)) and H∗ (stated in 4)), are not
equivalent.
4 Asymptotic Relative Efficiency
We extend the ARE method developed by Go´mez and Lagakos for time-to-event endpoints to binary end-
points. The extension relies on the asymptotic behaviours of the score tests T1,n for the relevant endpoint
given in (2) and T∗,n for the composite endpoint given in (5) presented in section 2, instead of the log-rank
test that was used for survival endpoints. In the following sections we present the ARE method and its
version for fixed alternatives.
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4.1 ARE method for contiguous alternatives
Consider the following not equivalent hypothesis tests based on the relevant endpoint and on the composite
endpoint:
H1,n :
{
H0 : log(OR1) = 0
H1,n : log(OR1)n =
v1√
n
H∗,n :
{
H0 : log(OR∗) = 0
H∗,n : log(OR∗)n = v∗√n
Let T1,n, T∗,n be the score tests corresponding to H1,n and H∗,n, respectively. Whereas under the null
hypothesis both tests asymptotically follow the standard normal distribution, under contiguous alternatives,
they are asymptotically N(δ1, 1) and N(δ∗, 1) with δ1 and δ∗ presented in (3) and (6), respectively. Both
tests behave as a displaced normal distribution according to the non-centrality parameter of the test, δ1 and
δ∗. Since the power of both tests is governed by the non-centrality parameters δ1 and δ∗, and the larger the
parameter is the greater the power (see Figure 1), a comparison between them yields a criterion for relative
efficiency. We define the ARE as the square of the ratio of the non-centrality parameters, that is:
ARE(T∗,n, T1,n) =
(
δ∗
δ1
)2
=
v2∗p
(0)
∗ q
(0)
∗
v21p
(0)
1 q
(0)
1
. (8)
ARE(T∗,n, T1,n) > 1 would imply larger powers if using ε∗ while ARE(T∗,n, T1,n) ≤ 1 would be in
favour of using ε1 as the best option for primary endpoint. Hence, choosing between ε1 or ε∗ is reduced
to a comparison between the two means of the asymptotic law under contiguous alternatives. The best
primary endpoint would be the one which has the greatest non-centrality parameter.
The method quantifies the differences in efficiency of using the composite or the relevant as primary
endpoint to lead the trial and, moreover, provides a decision rule to define the primary endpoint. If the ARE
is larger than 1, the composite endpoint may be considered the best option as primary endpoint. Otherwise,
the relevant endpoint is preferred. However, when the ARE value is in the vicinity of one, the advantages of
the composite endpoint over the relevant endpoint are too small to counteract the complicate interpretation
of the composite endpoint. Thus, under this circumstance, the relevant endpoint could be used instead as
primary endpoint.new
Summarizing, for every endpoint, given their event rates in the control group and their limiting treatment
effect, the ARE value captures which endpoint is more efficient for designing a clinical trial and provides
a criterion to choose among them.
4.2 ARE method for fixed alternatives
The ARE criterion to choose the primary endpoint given in (8) is based on alternative odds ratios which
are close to 1. From a practical point of view, the interest might often be on detecting treatment effects
ORk (k = 1, ∗), not necessarily near 1, and to address this we propose an approximated ARE value.
The efficiency criterion for fixed alternatives, based on the two-sample score tests T∗,n and T1,n, is
defined as:
are(p
(0)
1 , p
(0)
2 ,OR1,OR2, ρ
(0), ρ(1)) =
(log(OR∗))2p
(0)
∗ q
(0)
∗
(log(OR1))2p
(0)
1 q
(0)
1
(9)
Expression (9) approaches the ARE definition in (8) if for each endpoint, we would consider the fixed
treatment effect stabilized for the sample size as an approximate value for the limiting treatment, that is:√
n log(OR1) ∼= v1 and
√
n log(OR∗) ∼= v∗.
Hence, the decision on whether to use a composite binary endpoint versus its most relevant component
as the primary endpoint can be assessed by computing the ARE for fixed alternatives, referred to as are.
The are depends on the joint law of (Xij1, Xij2) (i = 0, 1) and can be determined by the following
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Figure 1 Asymptotic behavior of the score test under the null hypothesis (most right curve) and under
contiguous alternatives for each endpoint ε1 (most left curve) and ε∗ (second left).new
anticipated parameters: (i) p(0)1 and p
(0)
2 , event rates in control group for the relevant endpoint, ε1, and
the additional endpoint, ε2; (ii) OR1 and OR2 fixed treatment effects for ε1 and ε2; (iii) ρ(0) and ρ(1),
correlation between Xij1 and Xij2 for each group.
5 Case Study
Drug-eluting stents have been proved to reduce respenosis in noncomplex lesions, even so, their utility
has not been studied in a patient population with more complex lesions. TAXUS-V was a prospective,
multicenter, randomized trial to investigate the safety and efficacy of a placlitaxel-eluting stent in a patient
population with more complete lesions than previously studied (Stone, et al. (2005)). The trial was
conducted from February 2003 to March 2004 at 66 academic and community-based institutions with
1156 patients who underwent stent implantation in a single coronary artery stenosis, including 664 patients
(57.4%) with complex or previously unstudied lesions and 9-month clinical and angiographic follow-up.
Patients were randomly assigned to receive one or more bare metal stents (n = 579) or identical-appearing
paclitaxel-eluting stents (n = 577).
The primary endpoint was the 9-month incidence of ischemia-driven target vessel revascularization, ε1.
As a secondary endpoint, major adverse cardiac events, ε∗, were defined as ischemia-driven target-vessel
revascularization, ε1, or death from cardiac causes or myocardial infarction, ε2. The study shows that
compared with a bare metal stent, implantation of the paclitaxeleluting stent in a patient population with
complex lesions effectively reduces the rate of vessel revascularization.
For illustrative purposes, we assume that a study in a similar setting is to be planned, and the question
that arises is which primary endpoint should be used to lead the trial. We also assume that the results
of TAXUS-V are used for this purpose. Aiming to study whether it would be more efficient to base the
study on major adverse cardiac events, ε∗, instead of ischemia-driven target vessel revascularization, ε1,
we exemplify the use of the ARE method.
The frequency of target vessel revascularization in bare metal group is p(0)1 = 0.173, whereas the fre-
quency of death from cardiac causes or myocardial infarction is p(0)2 = 0.055. Furthermore, the frequencies
under the test group are p(1)1 = 0.121 and p
(1)
2 = 0.057, respectively. We discuss the use of the composite
endpoint as primary endpoint, for given values p(0)1 = 0.173, p
(0)
2 = 0.055 and p
(1)
1 = 0.121 and for the
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values for the parameter p(1)2 and ρ presented in Table 1. For given pairs (p
(0)
1 , p
(0)
2 ) and (p
(1)
1 , p
(1)
2 ) and
assuming equal correlation in both groups, the eligible values for ρ lie in the interval (−0.09, 0.53).
Table 1 Values of p(0)1 and p
(1)
1 , probability of target vessel revascularization in bare metal group and in
placitaxel-eluting group; p(0)2 and p
(1)
2 , probability of death from cardiac causes or myocardial infarction in
bare metal group and in placitaxel-eluting group; ρ, correlation among target vessel revascularization and
death from cardiac causes or myocardial infarction; OR1, odds ratio for target vessel revascularization;
OR2, odds ratio for death from cardiac causes or myocardial infarction, used for the discussion. The left
part of the table shows the treatment effects in terms of p, the right part shows the treatment effects in terms
of OR.
Parameter Values Parameter Values
p
(0)
1 0.173 p
(0)
1 0.173
p
(1)
1 0.121 OR1 0.67
p
(0)
2 0.055 p
(0)
2 0.055
p
(1)
2 0.057, 0.050, 0.045, 0.040, 0.035 OR2 1.04, 0.90, 0.81, 0.72, 0.62
ρ (−0.09, 0.53) ρ (−0.09, 0.53)
Figure 2 depicts the ARE values (in log scale) in terms of the correlation for each of the five different
values of the treatment effect on ε2. Observe that for a fixed correlation the ARE takes greater values as
the odds ratio OR2 for death from cardiac causes or myocardial infarction decreases. Therefore, the com-
posite endpoint becomes more effective and more useful when the odds ratio for the additional endpoint,
OR2, shows a greater treatment effect. Furthermore, notice that the ARE decreases when the correlation
increases, that is, the more correlated among target vessel revascularization and death from cardiac causes
or myocardial infarction are, the less appropriate necessary is the composite as primary endpoint.
Especially, when the odds ratio for death from cardiac causes or myocardial infarction, OR2, is equal
or larger than 0.81, the ARE is almost always less than 1 (see Figure 2). Hence, the use of target vessel
revascularization, ε1, provide more efficient detection of the differences between treatments. In the case
that OR2 ≤ 0.62new, the ARE is greater than 1. Then, the primary endpoint major adverse cardiac events,
ε∗, would have been more efficient instead of relevant endpoint. Finally, note that when OR2 is around
0.72, the decision depends on the value that correlation has.
6 Statistical efficiency guidelines
We have seen that the relative efficiency to choose between a composite endpoint or one of its relevant
components can be expressed in terms of the following anticipated parameters: treatment effects, event
rates and correlations. In this section, we discuss the influence that these parameters have on the relative
efficiency value. For example, which role does play the correlation between the two components in prefer-
ring the composite as primary endpoint? We conclude reporting guidelines which could be of some help
when designing a randomized clinical trial and facing the choice between several binary endpoints or their
combination.
6.1 Design
Our efficiency guidelines will be based on new event rates, p(0)1 , p
(0)
2 ,
new smaller than 0.1, odds ratios, OR1,
OR2,new between 0.5 and 1, and positive correlations (see Table 2)new. This choice is in accordance with
the values that are usually encountered in clinical trials. From now on, we assume that the correlations
are the same in the two groups and we denote it by ρ. Although Table 2 yields 436810 scenarios, sincenew
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Figure 2 ARE of major adverse cardiac events (death from cardiac causes, myocardial infarction, or
target-vessel revascularization) versus target-vessel revascularization for a range of correlation coefficient
and different values of OR2 for the parameters: p
(0)
1 = 0.173, p
(0)
2 = 0.055 and p
(1)
1 = 0.121. The plot
shows the curves of the are for each OR2 depending on the assumed ρ.
for every pair (p(0)1 , p
(0)
2 ) and (p
(1)
1 , p
(1)
2 ) not all the correlations are feasible, the total number of possible
scenarios is reduced to 315348.
Since the ARE method for fixed alternatives given in (9) depends on the parameters p(0)1 , p
(0)
2 , OR1,
OR2 and ρ, we calculate the are for each scenario. The ARE values that we have obtained has 1.52
as a median, and 0.81 and 4.82 as first and third quartile. We follow the principle that if are > 1, the
use of the composite endpoint is recommended, and if are ≤ 1, the relevant endpoint should be used
as primary endpoint. At last, we compute the percentage of cases on which the composite is preferred
over the relevant endpoint. We conclude with recommendations for the choice of the primary endpoint in
terms of the values of the correlations, the treatment effects and the event rates in control group for each
individual component. We have performed all computations using R software tool (Version 0.98.1087), the
time required to perform the considered scenarios was 16.58h.
As said earlier, when the ARE values are close to one,new in particular ifnew are ∈ (1, 1.1), the benefits
of using the composite endpoint over the relevant endpoint are small. Despite the value one is regarded
as the threshold of our study and is the focus of the subsequent discussion, guidelines using 1.1 as the
threshold for the decision can be viewed in Appendix B.
6.2 General pattern of the percentage of cases in which are > 1
We study the influence that the value of certain anticipated parameters, such as the treatment effect on the
relevant endpoint or the event rate of the additional endpoint, has on the selection between a composite
endpoint or its more relevant component as primary endpoint. As we will see, the most well-suited primary
endpoint might differ according to the anticipated parameters of the clinical trial.
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Table 2 Values of parameters p(0)1 , p
(0)
2 ,OR1,OR2 and ρ for the settings used for the efficient guidelines.
Parameter Values
p
(0)
1 , p
(0)
2 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.040, 0.045, 0.050, 0.055, 0.060, 0.065,
0.070, 0.075, 0.080, 0.085, 0.090, 0.095, 0.100
OR1, OR2 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 0.99
ρ 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9
Total scenarios 436810
Possible scenarios 315348
We have computed the are values for each of the 315348 scenarios described in Table 2 and in each case
we have recorded whether are > 1 –the composite endpoint would be recommendednew– or are ≤ 1 –the
relevant endpoint should be kept as primary endpoint–. A given scenario is characterized by the following
5 parameter values θ = (OR1,OR2, ρ, p
(0)
1 , p
(0)
2 ). Let P1(a) indicate the percentage of cases yielding
are > 1 among all the scenarios with OR1 = a. Analogously define Pj(a) as the percentage of cases
yielding are > 1 among all the scenarios with θj = a (j = 2, · · · , 5).
We have examined P1(OR1) for 0.5 ≤ OR1 < 1, P2(OR2) for 0.5 ≤ OR2 < 1 and P3(ρ) for
0 ≤ ρ ≤ 1. We observe that the percentage of situations in which are > 1 increases whenever: i) the
relative effect of treatment on the relevant endpoint increases, ii) the relative effect of treatment on the
additional endpoint decreases and iii) the correlation between the two endpoints decreases. In other words,
the number of situations where the composite endpoint is preferred is larger i) for larger values of OR1, ii)
for smaller values of OR2 and iii) for weakly correlated endpoints. Figure 3 and Figures 5, 6 (in Appendix
B) summarize these findings.
We have studied the behavior of P2(OR2) as a function of OR1. Figure 4 represents P2(OR2 =
OR1 + a) for OR1 = 0.6 and −0.10 ≤ a ≤ 0.35. We observe that the percentage of cases in which
the composite is preferred drops off rapidly when the effect of treatment is not as strong on the additional
endpoint as it is on the relevant endpoint (see Figures 7 and 8 when OR1 = 0.7 and OR1 = 0.8 in
Appendix B).
? = 0
  63% (CE)   73% (CE) 
? ?
Lower correlation 
?????????
1  
?????
2
Higher correlation 
??????????
1  
?????
2
 
? = 0.2
 67% (CE) 
? = 0.8
 58% (CE) 
? = 0.6
  60% (CE) 
are
? = 0.1 ? = 0.3 ? = 0.4 ? = 0.5 ? = 0.7 ? = 0.9
  71% (CE)   69% (CE)  65% (CE)  61% (CE)  60% (CE)  
Figure 3 Percentage of scenarios in which the composite endpoint should be used depending on ρ.
We have also studied the behavior of P4(p
(0)
1 ) for 0.01 ≤ p(0)1 ≤ 0.1 and of P5(p(0)2 ) for 0.01 ≤ p(0)2 ≤
0.1. There is a certain trend showing (plots not provided) that P4(p
(0)
1 ) decreases with p
(0)
1 while P5(p
(0)
2 )
increases with p(0)2 , indicating that less frequent event rates for the relevant endpoint and more frequent for
the additional endpoint are in the direction of preferring the composite endpoint. However, the values for
P4(p
(0)
1 ) or P5(p
(0)
2 ) are between 60% and 75%, implying that the other parameters (OR1,OR2, ρ) play a
more important role in the choice between the relevant and the composite endpoint.
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OR
1
-0.10
42% (RE)100% (CE) 89% (CE) 0% (RE)1% (RE)are 100% (CE)? ???% (CE) 7?% (CE) ??% (RE) 0% (RE)
OR
2
Lower relative risk of 
????????
2
Higher relative risk 
???????????
2
OR
2
OR
1
-0.05 OR
1
OR
1
+0.05 OR
1
+0.10 OR1+0.15 OR1+0.20 OR1+0.25 OR1+0.30 OR1+0.35
Figure 4 Percentage of scenarios in which the composite endpoint should be used depending on OR2
when OR1 = 0.6.
We have as well examined whether the behavior of the percentages P1(OR1) and P2(OR2) (see Figures
5 and 6) remains the same for different correlations ρ. We observe that the number of situations where the
composite endpoint is preferred increases when ρ decreases and either OR1 increases or OR2 decreases
(tables not provided).
6.3 Recommendations for the choice of the primary endpoint
We have splitted the recommendations into the following three cases: (I) when the correlation takes values
between 0 and 1 (0 < ρ < 1); (II) when the relevant and the additional endpoint are independent (ρ = 0);
and (III) when ρ = 1, implying that the relevant and the additional endpoint take the same value.
(I) Although the total number of scenarios that we have reproduced is very large and it has been useful
to understand how the are behaves, when it comes to anticipate parameter values on which to base our
decisions, accuracy cannot be as slim and is more realistic to render the recommendations to 3 or 4 cat-
egories of association, of strengths of the relative effect and of levels of frequency of the events. To this
end, we have chosen four degrees of association: weak (0 < ρ < 0.3), medium-weak (0.3 ≤ ρ < 0.6),
medium-strong (0.6 ≤ ρ < 0.8), strong (0.8 ≤ ρ < 1); three categories for treatment effect: Large for
Odds Ratios between 0.5 and 0.7, Medium for Odds Ratios between 0.7 and 0.9 and Low for Odds Ratios
between 0.9 and 1; and four event rates in control group for the relevant and additional endpoints, low
(p ≤ 0.025), medium-low (0.025 ≤ p ≤ 0.05), medium-large (0.05 ≤ p ≤ 0.075), large (p > 0.075).
To derive recommendations, for each case we provide the percentage of cases in which the composite is
preferred. On the basis of these percentages, we indicate whether the relevant or composite endpoint should
be used. We are considering here that if the percentage of are > 1 is larger than 60%, the recommendation
is to use of the composite endpoint; if the percentage is less than 40%, the recommendation is to use of the
relevant endpoint; otherwise, if the percentage lies between 40% and 60%, the recommendation cannot be
given. In this last case, we have reported that the recommendation is not conclusive and we have written
CE/RE. There are not conclusions for all situations, therefore, the ensuing computation of the ARE is
needed for the rest of particular situations.
Table 3 summarizes the recommendation in terms of the categories for (OR1,OR2). Basically, the
composite endpoint should be used when: i) treatment effect on the additional endpoint is large; ii) treat-
ment effects on the relevant and additional endpoint are medium; iii) treatment effects on the relevant and
additional endpoint are low and medium, respectively. On the other hand, the relevant endpoint is almost
always preferred if the treatment effect on the additional endpoint is low and the treatment effect on the
relevant is large or medium.
Recommendations taking into account the level of association together with the treatment effects on the
relevant and on the additional endpoint, event rates in control group for both the relevant and the additional
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Table 3 Recommendations in terms of treatment effects of the relevant and the additional endpoint, large
(0.5 ≤ OR < 0.7), medium (0.7 ≤ OR < 0.9) or low (0.9 ≤ OR < 1). Each cell indicates whether
the relevant endpoint (RE) (are ≤ 1) or composite endpoint (CE) (are > 1) should be used and, in
parentheses, the percentage of cases in which composite is preferred based on the scenarios described in
Table 2.
Large treatment Medium treatment Low treatment
effect on ε2 effect on ε2 effect ε2
Large treatment effect on ε1 CE (91.18%) RE (23.06%) RE (0%)
Medium treatment effect on ε1 CE (100%) CE (83.65%) RE (6.52%)
Low treatment effect ε1 CE (100%) CE (100%) CE (68.81%)
endpoint are summarized in Table 4. As earlier, we observe that the percentage of are > 1 decreases
as the degree of association increases. This underlines the importance of the correlation to decide the
primary endpoint. In particular, when the treatment effect either on the relevant or additional endpoint is
medium, the value of the correlation might play a crucial role in the decision. Notice that the percentages
of are > 1 in terms of the event rates are never larger than 75% or smaller than 50%, hence the frequency
of the relevant and additional endpoints cannot characterize by themselves the decision on which primary
endpoint to use.
Table 4 Recommendations in terms of degree of association between endpoints, weak (0 < ρ < 0.3),
medium-weak (0.3 ≤ ρ < 0.6), medium-strong (0.6 ≤ ρ < 0.8), strong (0.8 ≤ ρ < 1); treatment effects
of the relevant and the additional endpoint, large (0.5 ≤ OR < 0.7), medium (0.7 ≤ OR < 0.9) or low
(0.9 ≤ OR < 1); event rates in control group for the relevant and additional endpoints, low (p ≤ 0.025),
medium-low (0.025 ≤ p ≤ 0.05), medium-large (0.05 ≤ p ≤ 0.075), large (p > 0.075). Each cell
indicates whether the relevant endpoint (RE) (are ≤ 1) or composite endpoint (CE) (are > 1) should be
used and, in parentheses, the percentage of cases in which composite is preferred based on the scenarios
described in Table 2.
Correlation
Weak Medium-weak Medium-strong Strong
Large treatment effect on ε2 CE (99.72%) CE (97.41%) CE (92.87%) CE (84.97%)
Medium treatment effect on ε2 CE (74.96%) CE (65.97%) CE/RE (58.23%) CE/RE (56.96%)
Low treatment effect ε2 RE (23.61%) RE (21.39%) RE (20.99%) RE (28.16%)
Large treatment effect on ε1 CE/RE (49.80%) CE/RE (42.29%) RE (35.72%) RE (38.00%)
Medium treatment effect on ε1 CE (73.47%) CE (68.72%) CE (63.04%) CE/RE (57.78%)
Low treatment effect ε1 CE (92.16%) CE (91.05%) CE (89.87%) CE (86.61%)
Low event rate for ε1 CE (74.80%) CE (73.89%) CE (68.66%) CE (65.36%)
Medium-low event rate for ε1 CE (70.68%) CE (66.41%) CE (66.05%) CE (62.95%)
Medium-large event rate for ε1 CE (68.32%) CE (62.78%) CE/RE (59.01%) CE (62.14%)
Large event rate for ε1 CE (67.00%) CE (60.52%) CE/RE (53.29%) CE/RE (50.22%)
Low event rate for ε2 CE (66.63%) CE/RE (57.96%) CE/RE (53.87%) CE/RE (52.92%)
Medium-low event rate for ε2 CE (69.38%) CE (64.16%) CE/RE (55.77%) CE/RE (54.99%)
Medium-large event rate for ε2 CE (71.00%) CE (67.34%) CE (61.66%) CE/RE (55.46%)
Large event rate for ε2 CE (72.16%) CE (69.20%) CE (66.87%) CE (66.61%)
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(II) Whenever the relevant and additional endpoints are independent (ρ = 0), the composite endpoint
would be intuitively preferred, however this is not always the case as Figure 3 shows. Following the
rationale outlined above, Table 5 takes care of this situation. Note that the relevant endpoint is always
preferred to the composite endpoint when the treatment effect on the relevant endpoint is large and the
treatment effect on the additional endpoint is low. Besides, whenever the treatment effect on the relevant
endpoint is medium and the treatment effect on the additional endpoint is low, the relevant endpoint should
be the primary endpoint to lead the trial. Otherwise, if the treatment effect on the additional endpoint is
large (OR2 ≤ 0.7), the composite endpoint is always preferred.
Table 5 Recommendations in case of independence between the relevant and the additional endpoint
(ρ = 0) in terms of treatment effects of the relevant and the additional endpoint, large (0.5 ≤ OR < 0.7),
medium (0.7 ≤ OR < 0.9) or low (0.9 ≤ OR < 1). Each cell indicates whether the relevant endpoint
(RE) (are ≤ 1) or composite endpoint (CE) (are > 1) should be used and, in parentheses, the percentage
of cases in which composite is preferred based on the scenarios described in Table 2.
Large treatment Medium treatment Low treatment
effect on ε2 effect on ε2 effect ε2
Large treatment effect on ε1 CE (100%) CE/RE (48.84%) RE (0%)
Medium treatment effect on ε1 CE (100%) CE (96.36%) RE (15.12%)
Low treatment effect ε1 CE (100%) CE (100%) CE (76.55%)
(III) The case of ρ = 1 was excluded from the settings of scenarios because in this case are = 1. The
reason is that perfect linear dependence implies that the probabilities of the composite and the relevant
endpoint are the same. As a result, it can be seen by inspection of (9) that the resulting are is equal to one.
Hence, the decision rule sets up an equivalence between the relevant and composite endpoints in terms of
efficiency.
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7 Discussion
In this paper, we have proposed a method that allows an informed selection between a binary composite
endpoint or one of its components as primary endpoint. Although composite endpoints are widely used
as primary endpoints in clinical trials, as we have seen, they are not always the best option. The law
governing the composite endpoint depends on the event rates, the magnitude of the treatment effects and
the correlation between the components that form the composite. While the event rates and magnitude of
the treatment effects can be reasonably well anticipated, this is not the case for the correlation between
endpoints. Our methodology, and hence, the computation of the ARE has been established for different
correlation values in each treatment groupnew. However, the scenarios to derive the guidelines have been
restricted to the same correlation in both groups. The impact of this assumption as well as the scenarios
with two different correlations remain as future work.
If at least we could anticipate the degree of association in terms of weak, medium or large, we could
use Table 4 to decide which endpoint to use. The treatment effects of the relevant and the additional
endpoints also have an important role for deciding the primary endpoint. As seen earlier in Table 3, when
the additional endpoint presents a smaller treatment effect than the relevant endpoint, it could not be more
efficient to base the trial on the composite instead of the relevant endpoint, since the effect of the therapy
in these settings could be diluted by adding an endpoint.
In order to assess the appropriate choice of the primary endpoint, an interactive web-platform called
CompARE (https://cinna.upc.edu/compare) has been designed to calculate the ARE method based
on the information of the different endpoints together with anticipated values. This platform, initially
developed for time-to-endpoints, has not been extended in other frameworks. We are currently working on
extending the platform CompARE to address binary endpoints.
This paper has been restricted to composite endpoints defined by two components. The method could be
used for composite endpoints formed by more than two components by identifying two subsets of possible
components (SR and SA) and then comparing the composite versus one of its subsets, for instance, SR.
Furthermore, we could have used the difference (or ratio) of the event rates in both treatment groups
instead of the odds ratios to capture the treatment effects. The are method in terms of event rates is being
developed and is the focus of our future research.
The standard definition of the Asymptotic Relative Efficiency relates the efficiency of two statistic tests
for the same set of hypothesis. In this case, it can be interpreted as the limiting ratio of sample sizes to
give the same asymptotic power under sequences of contiguous alternatives (Noether (1954)). Go´mez
and Go´mez-Mateu (2014) empirically proved that the interpretation of the ARE as the ratio of required
sample sizes still holds when using two logrank tests to compare the hazard ratios under the relevant or the
composite endpoint. It remains to be seen whether the are we have proposed for binary endpoints can as
well be interpreted as a ratio of required sample sizes.
In this work the ARE method has been developed for discussing the use of a composite or one of its
components as primary endpoint. We have assumed that both endpoints, ε1 and ε2, are important enough to
be considered into the study and that one of the endpoints, ε1, is more relevant than the other, ε2. However,
the ARE method does not take into account the relative relevance between ε1 and ε2. We understand this
could be an important issue and remains open for future research.
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Appendix
A. Derivation of the Odds Ratio of a Binary Composite Endpoint
Theorem 7.1 Let Xij1 and Xij2 denote the responses of two binary endpoints for the j-th patient in
the i-th group of treatment (i = 0, 1, j = 1, ..., ni). Denote by Xij∗ the composite response defined as
Xij∗ =
{
1, if Xij1 +Xij2 ≥ 1
0, if else Xij1 +Xij2 = 0
Denote by p(i)1 = P(Xij1 = 1) = 1 − q(i)1 , p(i)2 = P(Xij2 = 1) = 1 − q(i)2 and p(i)∗ = P(Xij∗ =
1) = 1− q(i)∗ the probabilities of observing each endpoint in the i-th group, and by O(i)k the odds for each
endpoint in the i-th group, that is, O(i)k = p
(i)
k /q
(i)
k . Let OR1,OR2 be the odds ratio for both endpoints,
that is, ORk =
p
(1)
k /q
(1)
k
p
(0)
k /q
(0)
k
, (k = 1, 2). Let ρ(i) the correlation between Xij1 and Xij2 in group i, (i = 0, 1).
The Odds Ratio for the composite endpoint, OR∗, is determined by six parameters O
(0)
1 , O
(0)
2 , OR1,
OR2, ρ(0), ρ(1) and has the following expression:
OR∗ =
(
(1 + OR1O
(0)
1 )(1 + OR2O
(0)
2 )− 1− ρ(1)
√
OR1OR2O
(0)
1 O
(0)
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Hence:
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B. Results
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Figure 5 Percentage of scenarios in which the composite endpoint should be used depending on OR1.
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Figure 6 Percentage of scenarios in which the composite endpoint should be used depending on OR2.
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Figure 7 Percentage of scenarios in which the composite endpoint should be used depending on OR2
when OR1 = 0.7.
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Figure 8 Percentage of scenarios in which the composite endpoint should be used depending on OR2
when OR1 = 0.8.
Table 6 Recommendations in terms of treatment effects of the relevant and the additional endpoint, large
(0.5 ≤ OR < 0.7), medium (0.7 ≤ OR < 0.9) or low (0.9 ≤ OR < 1). Each cell indicates whether
the relevant endpoint (RE) (are ≤ 1.1) or composite endpoint (CE) (are > 1.1) should be used and, in
parentheses, the percentage of cases in which composite is preferred based on the scenarios described in
Table 2.
Large treatment Medium treatment Low treatment
effect on ε2 effect on ε2 effect ε2
Large treatment effect on ε1 CE (80.97%) RE (15.65%) RE (0.00%)
Medium treatment effect on ε1 CE (99.84%) CE (74.53%) RE (4.23%)
Low treatment effect ε1 CE (100.00%) CE (99.99%) CE (63.89%)
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ARE of major adverse cardiac events  (death from cardiac causes, myocardial infarction, or  target-vessel 
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$p_1^{(1)}=0.121$. The  plot shows the curves of the $are$ for each $\mathrm{OR}_2$ depending on the 
assumed $\rho$.  
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Percentage of scenarios in which the composite endpoint should be used depending on $\mathrm{OR}_2$ 
when $\mathrm{OR}_1=0.7$.  
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Percentage of scenarios in which the composite endpoint should be used depending on $\mathrm{OR}_2$ 
when $\mathrm{OR}_1=0.8$.  
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Asymptotic behavior of the score test under the  null  
hypothesis (most right curve)  and under contiguous  
alternatives for each endpoint $\varepsilon_1$ (most left curve)  
and $\varepsilon_*$ (second left).  
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